The DOI matches its Crossref record; 65 of the 66 references it cites were found in a registry or an index.
Sorafenib in Advanced Hepatocellular Carcinoma
Open accessAbstract
BACKGROUND: No effective systemic therapy exists for patients with advanced hepatocellular carcinoma. A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and Raf may be effective in hepatocellular carcinoma. METHODS: In this multicenter, phase 3, double-blind, placebo-controlled trial, we randomly assigned 602 patients with advanced hepatocellular carcinoma who had not received previous systemic treatment to receive either sorafenib (at a dose of 400 mg twice daily) or placebo. Primary outcomes were overall survival and the time to symptomatic progression. Secondary outcomes included the time to radiologic progression and safety. RESULTS: At the second planned interim analysis, 321 deaths had occurred, and the study was stopped. Median overall survival was 10.7 months in the sorafenib group and 7.9 months in the placebo group (hazard ratio in the sorafenib group, 0.69; 95% confidence interval, 0.55 to 0.87; P<0.001). There was no significant difference between the two groups in the median time to symptomatic progression (4.1 months vs. 4.9 months, respectively, P=0.77). The median time to radiologic progression was 5.5 months in the sorafenib group and 2.8 months in the placebo group (P<0.001). Seven patients in the sorafenib group (2%) and two patients in the placebo group (1%) had a partial response; no patients had a complete response. Diarrhea, weight loss, hand-foot skin reaction, and hypophosphatemia were more frequent in the sorafenib group. CONCLUSIONS: In patients with advanced hepatocellular carcinoma, median survival and the time to radiologic progression were nearly 3 months longer for patients treated with sorafenib than for those given placebo. (ClinicalTrials.gov number, NCT00105443.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“In previously untreated patients with advanced hepatocellular carcinoma, the approved multikinase inhibitors lenvatinib and sorafenib have provided modest median overall survival benefits of 13•6 months (lenvatinib) and 12•3 months (sorafenib).5,6”
From Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial (2025) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Multikinase inhibitors, including sorafenib and lenvatinib, are first-line treatment options for patients with unresectable hepatocellular carcinoma; however, they provide modest improvements in median overall survival (ranging from 12 months to 14 months), along with unsatisfactory safety outcomes.”
From Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial (2025) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Over the past two decades, the development of effective systemic therapies has substantially improved the outcomes of patients with advanced-stage HCC2–6.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The only FDA-approved drug for advanced HCC, sorafenib is well tolerated in cirrhotic patients (2) and inhibits several tyrosine kinases (e.g. VEGF, PDGFR, ERK/AKT, Ras, etc.), and their downstream oncogenic pathways (35).”
From Wnt-Pathway Activation in Two Molecular Classes of Hepatocellular Carcinoma and Experimental Modulation by Sorafenib (2012) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Of note, sorafenib performed exceptionally well in patients with non-viral HCCs, with a median OS reaching 18.1 months, considerably longer than that in the SHARP trial (10.7 months) or other sorafenib arms in recent phase three trials (13–15 months), which possibly cause the lack of comparative benefits for atezolizumab-bevacizumab in this subgroup despite preserved absolute benefits [27, 32, 33]”
From Etiology-Based Treatment for Unresectable/Advanced Hepatocellular Carcinoma: Focus on Viral Hepatitis and Metabolic Dysfunction-Associated Steatohepatitis (2025) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Ferlay, J., Ward, E., & Forman, D. (2011) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 55,044
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,710
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Transection of the oesophagus for bleeding oesophageal varices
Pugh, R. N. H., Murray-Lyon, I. M., Dawson, J. L., Pietroni, M. C., & Williams, R. (1973) · Journal of British Surgery · doi:10.1002/bjs.1800600817 · Cited by 7,941
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,913
Self-citationCheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Self-citationSorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B. J., Eisen, T. G., Stadler, W. M., Szczylik, C. A., Oudard, S. M., Siebels, M., Négrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
Self-citationClinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
Bruix, J., Sherman, M., Llovet, J. M., Beaugrand, M., Lencioni, R. A., Burroughs, A. K., Christensen, E., Pagliaro, L., Colombo, M., & Rodés, J. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00130-1 · Cited by 4,063
Self-citationWilhelm, S. M., Carter, C., Tang, L., Wilkie, D. P., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P. W., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,060
Flagged first, then by citations
1 of the 66 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Thomas MB, 2007, J Clin Oncol, 25, 214s
- Zhu AX, 2007, J Clin Oncol, 25, 231s
Cited by
Sorted by citations
Items 601–700 of 1,040
Surveillance, Diagnosis, Treatment, and Outcome of Liver Cancer in Japan
Kudo, M. (2015) · Liver Cancer · doi:10.1159/000367727 · Cited by 199
Ahmed, M., Barbáchano, Y., Riddell, A. M., Hickey, J. E., Newbold, K. L., Virós, A., Harrington, K. J., Marais, R., & Nutting, C. M. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0129 · Cited by 200
USP10 Promotes Proliferation of Hepatocellular Carcinoma by Deubiquitinating and Stabilizing YAP/TAZ
Zhu, H., Yan, F., Yuan, T., Qian, M., Zhou, T., Dai, X., Cao, J., Ying, M., Dong, X., He, Q., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2388 · Cited by 201
Hepatocellular Carcinoma Immunotherapy
Sperandio, R. C., Pestana, R. C., Miyamura, B. V., & Kaseb, A. O. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-042220-021121 · Cited by 199
Advanced-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization versus Sorafenib
Pinter, M., Hucke, F., Graziadei, I. W., Vogel, W., Maieron, A., Königsberg, R., Stauber, R. E., Grünberger, B., Müller, C., Kölblinger, C., et al. (2012) · Radiology · doi:10.1148/radiol.12111550 · Cited by 198
Kudo, M., Cheng, A., Park, J., Park, J. H., Liang, P., Hidaka, H., Izumi, N., Heo, J., Lee, Y. J., Sheen, I., et al. (2017) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(17)30290-x · Cited by 198
Niu, L., Liu, L., Yang, S., Ren, J., Lai, P. B. S., & Chen, G. G. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.10.002 · Cited by 198
Park, J., Kim, Y. J., Kim, D. Y., Bae, S. H., Paik, S. W., Lee, Y. J., Kim, H. Y., Lee, H. C., Han, S. Y., Cheong, J. Y., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.11.029 · Cited by 198
Immunotherapy for hepatocellular carcinoma: Current and future
Johnston, M. P., & Khakoo, S. I. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i24.2977 · Cited by 196
Phase 1/2 study of everolimus in advanced hepatocellular carcinoma
Zhu, A. X., Abrams, T. A., Miksad, R. A., Blaszkowsky, L. S., Meyerhardt, J. A., Zheng, H., Muzikansky, A., Clark, J. W., Kwak, E. L., Schrag, D., et al. (2011) · Cancer · doi:10.1002/cncr.26165 · Cited by 197
Kokudo, T., Hasegawa, K., Matsuyama, Y., Takayama, T., Izumi, N., Kadoya, M., Kudo, M., Kubo, S., Sakamoto, M., Nakashima, O., et al. (2017) · Hepatology · doi:10.1002/hep.29225 · Cited by 197
Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma
Hsiang-Chi, T., Xiong, W., Badeti, S., Yang, Y., Ma, M., Liu, T., Ramos, C. A., Dotti, G., Fritzky, L., Jiang, J.-G., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18444-2 · Cited by 198
Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma
Sonbol, M. B., Riaz, I. B., Naqvi, S. A. A., Almquist, D., Mina, S. A., Almasri, J., Shah, S., Almader‐Douglas, D., Usón, P. L. S., Mahipal, A., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.4930 · Cited by 197
The Landscape Of Alpha Fetoprotein In Hepatocellular Carcinoma: Where Are We?
Hu, X., Chen, R., Wei, Q., & Xu, X. L. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.64537 · Cited by 204
Han, K. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i36.10327 · Cited by 196
Shi, L., Yan, P., Liang, Y., Sun, Y., Shen, J., Zhou, S., Lin, H. M., Liang, X. H., & Cai, X. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.556 · Cited by 199
Chen, J., Lin, Z., Liu, L., Zhang, R., Geng, Y., Fan, M.-H., Zhu, W., Lü, M., Lu, L., Jia, H., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00784-0 · Cited by 193
Emerging Signaling Pathways in Hepatocellular Carcinoma
Moeini, A., Cornellà, H., & Villanueva, A. (2012) · Liver Cancer · doi:10.1159/000342405 · Cited by 197
Thrombotic Events in Patients With Cancer Receiving Antiangiogenesis Agents
Zangari, M., Fink, L. M., Elice, F., Zhan, F., Adcock, D. M., & Tricot, G. J. K. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.3875 · Cited by 195
Marquardt, J. U., Galle, P. R., & Teufel, A. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.07.007 · Cited by 194
Self-citationPhosphatidylserine: A cancer cell targeting biomarker
Sharma, B., & Kanwar, S. S. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.08.012 · Cited by 207
Li, W., Dong, X., He, C., Tan, G., Li, Z., Zhai, B., Feng, J., Jiang, X. L., Liu, C., Jiang, H., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1177-0 · Cited by 197
Hong, M., Li, S., Tan, H., Wang, N., Tsao, S., & Feng, Y. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161226126 · Cited by 201
Li, H., Li, X., Liu, S., Guo, L., Zhang, B., Zhang, J., & Ye, Q. (2017) · Hepatology · doi:10.1002/hep.29360 · Cited by 197
Zhu, A. X., Gold, P. J., El-Khoueiry, A. B., Abrams, T. A., Morikawa, H., Ohishi, N., Ohtomo, T., & Philip, P. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2616 · Cited by 193
Tumor Microenvironment, a Paradigm in Hepatocellular Carcinoma Progression and Therapy
Birgani, M. T., & Carloni, V. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020405 · Cited by 197
Chemotherapy for hepatocellular carcinoma: The present and the future
Grazie, M. L., Biagini, M. R., Tarocchi, M., Polvani, S., & Galli, A. (2017) · World Journal of Hepatology · doi:10.4254/wjh.v9.i21.907 · Cited by 191
Targeting the tumour vasculature: from vessel destruction to promotion
Guelfi, S., Hodivala‐Dilke, K., & Bergers, G. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00736-0 · Cited by 216
Treatment of advanced thyroid cancer with targeted therapies: ten years of experience
Viola, D., Valerio, L., Molinaro, E., Agate, L., Bottici, V., Biagini, A., Lorusso, L., Cappagli, V., Pieruzzi, L., Giani, C., et al. (2016) · Endocrine Related Cancer · doi:10.1530/erc-15-0555 · Cited by 191
Advances in resection and transplantation for hepatocellular carcinoma
Vibert, É., Schwartz, M., & Olthoff, K. M. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.11.017 · Cited by 191
Self-citationSignaling Pathways Governing Tumor Angiogenesis
Sakurai, T., & Kudo, M. (2011) · Oncology · doi:10.1159/000333256 · Cited by 193
Chen, Y., Chen, H., Wang, K., Zhang, L., Huang, Z., Liu, J., Zhang, Z., Luo, M., Lei, Y., Peng, Y., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.09.022 · Cited by 192
Sun, J., Zhou, C., Zhao, Y., Zhang, X.-F., Chen, W., Zhou, Q., Hu, B., Gao, D., Raatz, L., Wang, Z., et al. (2021) · Redox Biology · doi:10.1016/j.redox.2021.101942 · Cited by 190
Small molecule inhibitors targeting the cancers
Liu, G., Chen, T., Zhang, X., Ma, X., & Shi, H. (2022) · MedComm · doi:10.1002/mco2.181 · Cited by 212
Pin, L., Ge, M., Hu, J., Li, X., Che, L., Sun, K., Cheng, L., Huang, Y., Pilo, M. G., Cigliano, A., et al. (2017) · Hepatology · doi:10.1002/hep.29183 · Cited by 188
Major Challenges Limiting Liver Transplantation in the United States
Wertheim, J. A., Petrowsky, H., Saab, S., Kupiec‐Weglinski, J. W., & Busuttil, R. W. (2011) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03587.x · Cited by 188
Salem, R., Mazzaferro, V., & Sangro, B. (2013) · Hepatology · doi:10.1002/hep.26382 · Cited by 188
Self-citationCai, M., Huang, W., Huang, J., Shi, W., Guo, Y., Liang, L., Zhou, J., Lin, L., Cao, B., Chen, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.848387 · Cited by 191
“The multikinase inhibitors sorafenib and lenvatinib are recommended as the first-line treatment of advanced HCC (2– 4) on the basis of randomized trials demonstrating longer survival with sorafenib versus placebo (5, 6) and noninferiority of lenvatinib to sorafenib (7).”
BackgroundGlazer, E. S., Piccirillo, M., Albino, V., Giacomo, R. D., Palaia, R., Mastro, A. A., Beneduce, G., Castello, G., Rosa, V. D., Petrillo, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7765 · Cited by 187
Stabilized epoxygenated fatty acids regulate inflammation, pain, angiogenesis and cancer
Zhang, G., Kodani, S. D., & Hammock, B. D. (2013) · Progress in Lipid Research · doi:10.1016/j.plipres.2013.11.003 · Cited by 193
Marisi, G., Cucchetti, A., Ulivi, P., Canale, M., Cabibbo, G., Solaini, L., Foschi, F. G., Matteis, S. D., Ercolani, G., Valgiusti, M., et al. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i36.4152 · Cited by 187
Role of microRNA-199a-5p and discoidin domain receptor 1 in human hepatocellular carcinoma invasion
Shen, Q., Cicinnati, V. R., Zhang, X., Iacob, S., Weber, F., Sotiropoulos, G. C., Radtke, A., Lu, M., Paul, A., Gerken, G., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-227 · Cited by 192
Cancer gene discovery in hepatocellular carcinoma
Zender, L., Villanueva, A., Tovar, V., Sia, D., Chiang, D. Y., & Llovet, J. M. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2009.12.034 · Cited by 187
Self-citationLambrechts, D., Claes, B., Delmar, P., Reumers, J., Mazzone, M., Yesilyurt, B. T., Devlieger, R., Verslype, C., Tejpar, S., Wildiers, H. P. M. W., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70231-0 · Cited by 187
Caruso, S., Calatayud, A.-L., Pilet, J., Bella, T. L., Rekik, S., Imbeaud, S., Letouzé, É., Meunier, L., Bayard, Q., Rohr‐Udilova, N., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.05.001 · Cited by 186
Involvement of platelet‐derived growth factor ligands and receptors in tumorigenesis
Heldin, C. ‐., Lennartsson, J., & Westermark, B. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12690 · Cited by 181
MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a
Toffanin, S., Hoshida, Y., Lachenmayer, A., Villanueva, A., Cabellos, L., Minguez, B., Savic, R., Ward, S. C., Thung, S., Chiang, D. Y., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.009 · Cited by 232
Self-citationKocabayoglu, P., Lade, A. G., Lee, Y. A., Dragomir, A.-C., Sun, X., Fiel, M. I., Thung, S. N., Aloman, C., Soriano, P. M., Hoshida, Y., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.01.036 · Cited by 186
Horwitz, E. P., Stein, I., Andreozzi, M., Németh, J., Shoham, A., Pappo, O., Schweitzer, N., Tornillo, L., Kanarek, N., Quagliata, L., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0782 · Cited by 185
van Malenstein, H., Dekervel, J., Verslype, C., Cutsem, E. V., Windmolders, P., Nevens, F., & van Pelt, J. F. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.10.021 · Cited by 185
Androgen receptor roles in hepatocellular carcinoma, fatty liver, cirrhosis and hepatitis
Ma, W., Lai, H.-C., Yeh, S., Cai, X., & Chang, C. (2014) · Endocrine Related Cancer · doi:10.1530/erc-13-0283 · Cited by 188
Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma
Zhai, B. (2013) · World Journal of Hepatology · doi:10.4254/wjh.v5.i7.345 · Cited by 184
Are there opportunities for chemotherapy in the treatment of hepatocellular cancer?
Asghar, U. S., & Meyer, T. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.07.031 · Cited by 184
MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1
Li, H., Li, C., Li, X., Ding, Q., Guo, L., Liu, S., Liu, C., Lai, C., Hsu, J.-M., Dong, Q., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.01.252 · Cited by 189
Liu, Z., Wang, Q., Wang, X., Xu, Z., Wei, X., & Li, J. (2020) · Cell Death Discovery · doi:10.1038/s41420-020-00306-x · Cited by 187
Drug-induced Hypertension: An Unappreciated Cause of Secondary Hypertension
Grossman, E., & Messerli, F. H. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.05.024 · Cited by 183
Pazopanib: Clinical development of a potent anti-angiogenic drug
Schutz, F. A. B., Choueiri, T. K., & Sternberg, C. N. (2010) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2010.02.012 · Cited by 185
Liu, L., Zhu, X., Wang, W., Shen, Y., Qin, Y., Ren, Z., Sun, H., & Tang, Z. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2610 · Cited by 187
Management of hepatocellular carcinoma with portal vein tumor thrombosis: Review and update at 2016
Chan, S. L., Chong, C. C. N., Chan, A. W. H., Poon, D. M. C., & Chok, K. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i32.7289 · Cited by 183
Hypoxia-inducible factors and innate immunity in liver cancer
Yuen, V. W., & Wong, C. C. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137553 · Cited by 187
Eggelpoël, M.-J. B.-V., Chettouh, H., Fartoux, L., Aoudjehane, L., Barbu, V. D., Rey, C., Priam, S., Housset, C., Rosmorduc, O., & Desbois‐Mouthon, C. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.02.019 · Cited by 182
Mannelli, L., Kim, S., Hajdu, C. H., Babb, J. S., Clark, T. W. I., & Taouli, B. A. (2009) · American Journal of Roentgenology · doi:10.2214/ajr.08.1461 · Cited by 182
Torrecilla, S., Sia, D., Harrington, A., Zhang, Z., Cabellos, L., Cornellà, H., Moeini, A., Campreciós, G., Leow, W. Q., Fiel, M. I., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.08.013 · Cited by 184
Self-citationSarker, D., Plummer, R., Meyer, T., Sodergren, M. H., Basu, B., Chee, C. E., Huang, K., Palmer, D. H., Ma, Y. T., Evans, T. R. J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0414 · Cited by 182
Bolondi, L., Cillo, U., Colombo, M., Craxí, A., Farinati, F., Giannini, E., Golfieri, R., Levrero, M., Pinna, A., Piscaglia, F., et al. (2013) · Digestive and Liver Disease · doi:10.1016/j.dld.2013.01.012 · Cited by 190
Self-citationMet as a therapeutic target in HCC: Facts and hopes
Giordano, S., & Columbano, A. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.09.009 · Cited by 158
FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib
Gao, L., Wang, X., Tang, Y., Huang, S., Hu, C.-A. A., & Teng, Y. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0478-9 · Cited by 180
Brown, D. B., Nikolic, B., Covey, A. M., Nutting, C. W., Saad, W. E. A., Salem, R., Sofocleous, C. T., & Sze, D. Y. (2012) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2011.11.029 · Cited by 181
Role of the VEGF/VEGFR Axis in Cancer Biology and Therapy
Rapisarda, A., & Melillo, G. (2012) · Advances in cancer research · doi:10.1016/b978-0-12-386503-8.00006-5 · Cited by 186
Ogasawara, S., Chiba, T., Ooka, Y., Kanogawa, N., Motoyama, T., Suzuki, E., Tawada, A., Kanai, F., Yoshikawa, M., & Yokosuka, O. (2014) · Oncology · doi:10.1159/000365993 · Cited by 180
Pignochino, Y., Grignani, G., Cavalloni, G., Motta, M., Tapparo, M., Bruno, S., Bottos, A., Gammaitoni, L., Migliardi, G., Camussi, G., et al. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-118 · Cited by 182
Nagl, L., Horvath, L., Pircher, A., & Wolf, D. G. F. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00766 · Cited by 189
Dai, H., Tong, C., Shi, D., Chen, M., Guo, Y., Chen, D., Han, X., Wang, H., Wang, Y., & Shen, P. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1846926 · Cited by 182
Models for prevention and treatment of cancer: Problems vs promises
Aggarwal, B. B., Danda, D., Gupta, S. R., & Gehlot, P. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.05.027 · Cited by 184
Mitogen-activated protein kinases in hepatocellular carcinoma development
Min, L., He, B., & Hui, L. (2010) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2010.10.011 · Cited by 179
Hecht, J. R., Trarbach, T., Hainsworth, J. D., Major, P. P., Jäger, E., Wolff, R. A., Lloyd-Salvant, K., Bodoky, G., Pendergrass, K. B., Berg, W. J., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.4496 · Cited by 177
Lee, D., Xu, M., Chiu, D. K., Leibold, J., Tse, A. P., Bao, M. H., Yuen, V. W., Chan, C. Y., Lai, R. K., Chin, D. W., et al. (2018) · Hepatology · doi:10.1002/hep.30467 · Cited by 183
Jin, H., Wang, S., Zaal, E. A., Wang, C., Wu, H.-Q., Bosma, A. R., Jochems, F., Isima, N., Jin, G., Lieftink, C., et al. (2020) · eLife · doi:10.7554/elife.56749 · Cited by 183
Ezzoukhry, Z., Louandre, C., Trécherel, E., Godin, C., Chauffert, B., Dupont, S., Diouf, M., Barbare, J., Mazière, J., & Galmiche, A. (2012) · International Journal of Cancer · doi:10.1002/ijc.27604 · Cited by 176
STAT proteins – Key regulators of anti-viral responses, inflammation, and tumorigenesis in the liver
Gao, B., Wang, H., Lafdil, F., & Feng, D. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.01.029 · Cited by 180
Sorafenib in Unresectable Hepatocellular Carcinoma from Mild to Advanced Stage Liver Cirrhosis
Pinter, M., Sieghart, W., Graziadei, I. W., Vogel, W., Maieron, A., Königsberg, R., Weißmann, A., Kornek, G. V., Plank, C. M., & Peck‐Radosavljevic, M. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0191 · Cited by 177
Virus associated malignancies: The role of viral hepatitis in hepatocellular carcinoma
Shlomai, A., de Jong, Y. P., & Rice, C. M. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.01.004 · Cited by 186
Challenges of advanced hepatocellular carcinoma
Colagrande, S., Inghilesi, A. L., Aburas, S., Taliani, G. G., Nardi, C., & Marra, F. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i34.7645 · Cited by 177
Ma, M. K. F., Lau, E. Y.-T., Leung, H.-W., Lo, J. H. T., Ho, N. P. Y., Cheng, L. K., Ma, S., Lin, C. H., Copland, J. A., Ding, J., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.06.015 · Cited by 178
Pathogenesis and Current Treatment Strategies of Hepatocellular Carcinoma
Tümen, D., Heumann, P., Gülow, K., Demirci, C. N., Cosma, L.-S., Müller, M., & Kandulski, A. (2022) · Biomedicines · doi:10.3390/biomedicines10123202 · Cited by 192
Rimassa, L., Chan, S. L., Sangro, B., Lau, G. K. K., Kudo, M., Reig, M., Breder, V. V., Ryu, M., Ostapenko, Y., Sukeepaisarnjaroen, W., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.03.033 · Cited by 190
Severi, T., van Malenstein, H., Verslype, C., & van Pelt, J. F. (2010) · Acta Pharmacologica Sinica · doi:10.1038/aps.2010.142 · Cited by 182
Mazzocca, A., Fransvea, E., Dituri, F., Lupo, L., Antonaci, S., & Giannelli, G. (2009) · Hepatology · doi:10.1002/hep.23285 · Cited by 180
Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia
Rapisarda, A., & Melillo, G. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.64 · Cited by 178
Cutaneous adverse effects of targeted therapies
Macdonald, J. B., Macdonald, B., Golitz, L. E., LoRusso, P. M., & Sekulić, A. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.07.033 · Cited by 178
Greten, T. F., Wang, X. W., & Korangy, F. (2015) · Gut · doi:10.1136/gutjnl-2014-307990 · Cited by 178
Self-citationVincenzi, B., Santini, D., Russo, A. D., Addeo, R., Giuliani, F., Montella, L., Rizzo, S., Venditti, O., Frezza, A. M., Caraglia, M., et al. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0143 · Cited by 175
Ou, W., Mulik, R. S., Anwar, A., McDonald, J. G., He, X., & Corbin, I. R. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.09.002 · Cited by 179
The Role of MicroRNAs in Hepatocellular Carcinoma
Xu, X., Tao, Y., Shan, L., Chen, R., Jiang, H., Qian, Z., Cai, F., Ma, L., & Yu, Y. (2018) · Journal of Cancer · doi:10.7150/jca.26350 · Cited by 179
Hepatocellular carcinoma: From diagnosis to treatment
Waghray, A. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i8.1020 · Cited by 178
Kuczynski, E. A., Yin, M., Bar‐Zion, A., Lee, C. R., Butz, H., Man, S., Daley, F. M., Vermeulen, P., Yousef, G. M., Foster, F. S., et al. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw030 · Cited by 175
Maitland, M. L., Kasza, K., Karrison, T. G., Moshier, K., Sit, L., Black, H. R., Undevia, S. D., Stadler, W. M., Elliott, W. J., & Ratain, M. J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0058 · Cited by 176
Tang, H., Chen, D., Li, C., Zheng, C., Wu, X., Zhang, Y., Song, Q., & Fei, W. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118782 · Cited by 175
Zhou, T., Liang, X., Wang, P., Hu, Y., Qi, Y., Jin, Y., Du, Y., Fang, C., & Tian, J. (2020) · ACS Nano · doi:10.1021/acsnano.0c01453 · Cited by 173
Metadata
- Authors
- Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., Schwartz, M., Porta, C., Zeuzem, S., Bolondi, L., Greten, T. F., Galle, P. R., Seitz, J.-F., Borbath, I., Häussinger, D., Giannaris, T., Shan, M., Moscovici, M., Voliotis, D., & Bruix, J.
- Affiliations
- Hospital Clínic de Barcelona (ES)
- University of Pisa (IT)
- Auckland City Hospital (NZ)
- Cliniques Universitaires Saint-Luc (BE)
- Université Européenne de Bretagne (FR)
- Centro de Investigación Biomédica en Red (ES)
- Goethe University Frankfurt (DE)
- Medizinische Hochschule Hannover (DE)
- Johannes Gutenberg University Mainz (DE)
- Aix-Marseille Université (FR)
- Bayer (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-07-24
- Volume
- 359
- Issue
- 4
- Pages
- 378-390
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1971837077
- Cited by
- 13,097
- References
- 66
- Citations by year
- 2026: 390 · 2025: 623 · 2024: 729 · 2023: 874 · 2022: 1003 · 2021: 1093 · 2020: 971 · 2019: 816 · 2018: 746 · 2017: 814 · 2016: 704 · 2015: 730 · 2014: 753 · 2013: 695 · 2012: 624
- FWCI
- 369.86
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Falk Foundation
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Exelixis
- Bayer HealthCare
- Eisai
- Merz Pharmaceuticals
- Ipsen
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Keywords
- sorafenib, hepatocellular carcinoma, multikinase inhibitor, VEGFR, PDGFR, Raf, overall survival, adverse effects, hand-foot skin reaction, hypophosphatemia, diarrhea, weight loss
- MeSH terms
- Sorafenib, Aged, Benzenesulfonates, Double-Blind Method, Female, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Male, Middle Aged, Neoplasm Staging, Niacinamide, Phenylurea Compounds, Pyridines, Proportional Hazards Models, Survival Analysis, Chemotherapy, Adjuvant, Disease Progression, Protein Kinase Inhibitors, raf Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
